Abstract:【Objective】To investigate the clinical efficacy of growth hormone combined with low-molecular-weight heparin in the frozen embryo cycle of patients with recurrent implantation failure. 【Methods】A retrospective analysis from Reproductive Center of Hunan Maternal and Child Health Hospital was studied on the clinical effect of 73 assisted-reproduction patients with recurrent implantation failures during 2017-2018. According to different treatment methods, patients were divided into the observation group (n=52) and the control group (n=21). Conventional hormone replacement program was used in the control group, while growth hormone combined with low molecular weight heparin was applied in the observation group. The endometrial condition and pregnancy outcome of the two groups were compared. 【Results】The comparison of the endometrial thickness of the corpus luteum transformation, percentage of normal endometrial morphology, and implant day endometrial thickness between the observation group and the control group were: 9.9±1.9 mm vs 9.3±0.8 mm、86.5% vs 80.9% and 10.3±1.9 mm vs 9.4±0.7 mm, respectively. The differences were statistically significant (P<0.05). The clinical pregnancy rate, embryo implantation rate, and live birth rate of the observation group were 38.5 %, 24.2%, and 26.9%, respectively, while those rates of the control group were 28.6%, 16.3% and 19.0%, respectively. There were no statistically significant differences (P>0.05). 【Conclusion】After the application of growth hormone combined with low molecular weight heparin in the frozen embryo cycle of patients with recurrent implantation failure, it can effectively improve the thickness and morphology of endometrium, which enhances endometrial receptivity. It provides a new idea for the strategy of assisted pregnancy for patients with recurrent implantation failure, though the embryo implantation rate, clinical pregnancy rate, and live birth rate of the study group were not really increased.
[1] Polanski LT, Baumgarten MN, Quenby S, et al.What exactly do we mean by 'recurrent implantation failure'? A systematic review and opinion[J].Reprod Biomed Online,2014,28(4):409-423.
[2] Xu YM,Hao GM, Gao BL.Application of growth hormone in in vitro fertilization[J].Front Endocrinol,2019 ,10:502.
[3] 莫凤媚.生长激素对女性生殖系统的影响及其在辅助生殖中的应用[J].广西医学,2018,40(13):1479-1482.
[4] Liu FT, Wu Z, Yan J, et al. The potential role of growth hormone on the endometrium in assisted reproductive technology[J].Front Endocrinol,2020,11: 49.
[5] 李秀清,高小琴,韩雪黎,等.多次胚胎移植失败生长激素对子宫内膜及内膜血流的影响[J].实用医技杂志,2014,21(12):1333-1335.
[6] Altm e S, Mendoza-Tesarik R, Mendoza C, et al.Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donation program: a randomized controlled trial[J].J Endocr Soc,2017,2(1):96-105.
[7] 谭小方,施蔚虹,邵骏,等.胚胎反复种植失败不孕症患者血清 AT-III活性、D二聚体水平及血小板聚集率变化[J].山东医药,2016,56(19):70-71.
[8] 郭艺红,孙莹璞. 控制性卵巢刺激与凝血功能[J].实用妇产科杂志,2019, 35(5):337-340.
[9] Bellver J,Soares SR,Alvarez C,et al.The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion[J].Hum Reprod,2008,23(2):278-284.
[10] 赵爱民.低分子肝素防治自然流产中国专家共识(2018)[J].中华生殖与避孕杂志,2018,38(9):701-708.
[11] 赵琳琳,安红歌,伦宝艳,等.高龄产妇采用低分子肝素钙预防产后深静脉血栓的疗效与安全性探讨[J].中国医师杂志,2018,20(2):738-740.
[12] Shomer E, Katzenell S, Zipori Y, et al. Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function [J].Thromb Res,2016, 137:141-147.
[13] Potdar N,Gelbaya TA,Konje JC,et al.Adjunct low- molecular-weight heparin to improve live birth rate after recurrent implantation failure:a systematic review and meta-analysis[J].Hum Reprod Update,2013,19(6):674-684.
[14] Noci I, Milanini MN, Ruggiero M, et al. Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study[J].Reprod Biomed Online,2011,22(6):615-620.